Drug Profile
Entrectinib companion diagnostic - Ignyta
Alternative Names: Trailblaze Pharos™Latest Information Update: 10 Mar 2021
Price :
$50
*
At a glance
- Originator ArcherDX; Ignyta
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 10 Mar 2021 Phase II trial is still ongoing in Solid tumours (Diagnosis) in Australia, France, Germany, Hong Kong, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, Taiwan, USA, United Kingdom, China, Belgium (NCT02568267)
- 08 Jan 2019 Entrectinib companion diagnostic receives breakthrough device designation in USA
- 15 Nov 2016 Trailblaze Pharos companion diagnostic test receives Expedited Access Pathway (EAP) designation and CE markings in USA and Europe Union